confirmed by PCR, sequencing as well as immunofluorescence and immunoblot analyses.
The B5R-P189S virus particles was detected with anti-B5R 19C2 rat monoclonal (6) while the B5R-SCR4 virus was detected with anti-A27L (p14) (7) or anti-A36R (8) as it lacks the 19C2 epitope.
In vitro kinase and binding assays DNA corresponding to amino acids 24-118 of A36R and A36R-Y112F were amplified by PCR and cloned in the Not I -EcoRI sites of the T7 bacterial expression vector pMW-GST.
GST, GST-A36R 24-118 and GST-A36R 24-118 Y112F were produced by leaky expression overnight in BL21 (DE3) and purified from the soluble fraction according to the manufacturer's instructions (Amersham Bioscience, Uppsala, Sweden). The resulting purified GST fusion proteins were dialysed, quantified and rebound to Glutathione sepharose beads prior to in vitro Src kinase assays which were performed according to the manufacturer's instructions using 0.4-3.6 Units of kinase per reaction (Oncogene, SanDiego, USA). Following phosphorylation, the beads with bound GST or GST-A36R fusion proteins were incubated with soluble E. coli extracts containing His-Nck (3). The beads were subsequently incubated with cell extracts prepared from 293T cells expressing the cargobinding region of mouse kinesin light chain 2 as a GFP fusion (GFP-TPR) (2) . Immunoblot analysis was subsequently performed with anti-His (Sigma, Poole, UK), anti-P-tyr (4G10, Upstate, Milton Keynes, UK) and anti-GFP (3E1, Cancer Research UK, London, UK) antibodies.
Antibodies
Infected cells were labelled with antibodies against the IMV protein A27L (p14) (7) or the IEV proteins A36R or B5R (19C2 rat monoclonal) (6, 8) . Rabbit polyclonal antibodies, 2 Newsome 3 were raised against the phosphorylated peptide (EQTIpYQNTT) corresponding to residues 128-136 of A36R, that was coupled, via an N-terminal cysteine-glycine-glycine linker to Keyhole Limpet hemocyanin using the Imject activated immunogen conjugation kit (Pierce Chemical Co, Rockford, IL, USA). Phospho-specific antibodies were affinity purified from the rabbit serum on the phospho-peptide coupled via the N-terminal cysteine to SulfoLink column (Pierce Chemical Co.) after pre-clarification over a similarly coupled non-phosphoversion of the peptide. Src was detected with MAb 3-27 (9) or rabbit polyclonal antisera (Sc18, Santa Cruz Biotechnology, California, USA). Cortactin was visualized with MAb 4F11 (Upstate Biotechnology, New York, USA). Phosphospecific antibodies against Src (pY418) and Cortactin (pY421) were purchased from Biosource (California, USA).
Conventional kinesin was visualized with monoclonal antibodies MAB1616 (L1), MAB1617 (L2), MAB1613 (H1), MAB1614 (H2), which detect the light and heavy chains of the motor (Chemicon International, Inc. California, USA). F-actin was visualized with Alexa 488-or
Alexa 568-phalloidin (Molecular Probes, Eugene, OR, USA).
Immunofluorescence, Src-GFP expression vectors and transfection. 8 hours post infection cells were processed for either immunoblot or immunofluorescence analysis as described previously (8, 10) . Extracellular CEV were detected by labelling infected cells with anti-B5R antibody after fixation but prior to cell permeablization with Triton X-100. Src-GFP, which was kindly provided by Giulio Superti-Furga (EMBL, Germany), was cloned into the BglII/NotI sites of the vaccinia promoter driven pEL expression vector (5) . The "dead-open" dominant negative pEL-Src 527Kin -was previously described (5) . HeLa cells were transfected with pEL-Src-GFP and pEL-Src 527Kin -4 hours post infection and fixed 4 hours later for immunofluorescence analysis as previously described (5). In the last step, phosphorylated A36R recruits the vaccinia actin tail-nucleating complex (Grb2, Nck, WIP and N-WASP), which leads to localized activation of the Arp2/3 and actin polymerization. Premature phosphorylation of A36R at the site of IEV assembly inhibits kinesin recruitment and blocks movement of virus particles to the plasma membrane (step 1).
Alternatively, inhibition of Src signaling prevents release of conventional kinesin at the plasma membrane beneath the CEV (step 4).
